SUCCESSFUL IMMUNOTHERAPY WITH IMIQUIMOD IN VAGINAL INTRAEPITHELIAL LESION – A CASE REPORT

1Damir Danoli, 1Luka Maročić, 1Lucija Šušnjar, 1Ilja Alvić, 2Vica Mamić, 2Danijela Danolić, 3Simun Puljiz, 1Mario Puljiz. 1Department of Gynaecologic Oncology, University Hospital Centre, Zagreb; 2Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi; 3School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina

Introduction/Background: Imiquimod is an immune response stimulator often used in the management of various clinical manifestations of human papillomavirus (HPV) infections. Surgical treatment of vaginal intraepithelial lesions is often difficult and not always feasible. According to literature therapy with 5% imiquimod seems to be a safe mode of treatment for high grade genital intraepithelial lesions (HSIL) in selected patients, especially for vaginal and vulvar HSIL. The aim of this report is to present 5% imiquimod therapy as an alternative to surgical procedures in patient with vaginal intraepithelial lesion.

Methodology: A 55-year-old postmenopausal woman was referred to our department with high-grade squamous intraepithelial lesion (HSIL) and HPV-related changes on her Pap test. Also, the patient presented with lesion on left vaginal fornix which cytology result was consistent with SIL. The patient underwent conization, resulting in a pathological diagnosis of grade 2/3 cervical intraepithelial neoplasia (CIN). Also, excision of vaginal lesion in left fornix revealed vaginal intraepithelial neoplasia (VaIN) grade 2/3. Neoplastic changes involved resection margins on both specimens. Total abdominal hysterectomy with resection of vaginal fornices and bilateral salpingo-oophorectomy were performed. Histological examination revealed VaIN 3. One year after the surgery, a follow-up vaginal smear demonstrated VaIN 1. Therefore, biopsy was performed leading to a pathological diagnosis of VaIN 1/2. Treatment was initiated with topical imiquimod 5% cream, three times per week, for 8 weeks.

Results: Follow-up vaginal smear and colposcopy findings after completion of therapy were all negative for intraepithelial lesion or malignancy. As of 4 years after the imiquimod treatment, there has been no signs of recurrence.

Conclusion: Combined treatment modalities may hold the key to optimal treatment of genital HSILs and the treatment must always be individualized. However, there are currently no studies assessing efficacy of imiquimod topical treatment with traditional surgical modes of treatment.

ROLE OF PLASTIC SURGERY FOLLOWING RESECTION OF VULVAL TUMOURS: IS COLLABORATION THE KEY?

1Maneesh Singhal, 2Seema Singhal, 3Shashank Chauhan, 4Suvashis Dash, 5Swashish Dash, 6Shivangi Saha, 7Shruthi Chandrasekar, 8Nandini Singh, 3Amit Mandal, 4Anju Singh, 6Neena Malhotra, 5Neerja Bhatia. 1Plastic and Reconstructive Surgery, All India Institute of Medical Sciences, New Delhi, India; 2Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India

Introduction/Background: Reconstruction of the vulva following extirpative surgeries is essential in restoring the form and functions of daily living. Complex defect reconstruction can be difficult and may necessitate collaboration between gynaecology and reconstructive surgeons. We present our experience in the reconstruction of vulvar defects following tumour excision (benign and malignant) and in the management of post inguinal lymph node dissection (ILND) lymphorrhoea.

Methodology: A prospective study was conducted between 2020–2022. All patients (N=8) requiring plastic surgical intervention were included. Five patients with vulval tumours underwent reconstruction. Three patients having ILND lymphorrhoea and other malignant vulval tumours were managed conservatively with low pressure negative wound therapy (NPWT).

Results: The median age was 50.4 years (28–63 years), requiring a mean hospital stay of 13.6 days. Two cases of vulval squamous cell carcinoma underwent local VY advancement flap and a pedicled anterolateral thigh flap, respectively. One case of primary vulval lymphedema was managed with debulking and reconstruction of the labia majora and minora with vulval flaps. Two benign tumours of the vulva (fibromatoses) required W-plasty and VY advancement flap respectively. One patient had vulval wall necrosis and partial flap dehiscence in the immediate post-operative period. No long-term delayed complications were observed in our patients at a mean follow-up of 3 months. The mean length of hospital stay for inguinal lymphorrhoea was not significantly higher than that for those undergoing reconstructive surgery.

Conclusion: Reconstructive surgery improves pain, function, and early postoperative recovery. Application of NPWT is an effective modality for treating inguinal lymphorrhoea. Collaboration with the plastic surgery team is essential in achieving the same for the benefit of such patients.

HUMAN PAPILLOMAVIRUS-ASSOCIATED AND INDEPENDENT VULVAR SQUAMOUS CELL CARCINOMAS: CLINICAL, PATHOLOGICAL AND PROGNOSTIC DISTINCT ENTITIES

1Núria Camareras-Dieguéz, 2Carolina Manesotti, 3Lorena Marimon, 4Ricardo López del Campo, 5Pedro Jares, 5Clàudia Pumarola, 6Pere Fusté, 7Berta Díaz Feijoo, 8Iñaki Glickman, 9Núria Agustí, 10Tiemers Marina, 11Adela Sacó, 12Marta del Pino, 13Aureli Torné, 14Natalia Rakislova. 1Gynaecologic Oncology Unit, Hospital Clínico de Barcelona, Barcelona, Spain; 2Obstetrics and Gynaecology Department, Hospital Clinic de Barcelona, Barcelona, Spain; 3Obstetrics and Gynaecology Department, Hospital Clinic de Barcelona, Barcelona, Spain; 4Pathology Department, ISGlobal, Barcelona, Spain; 5Pathology Department, Hospital Clínico de Barcelona, Barcelona, Spain; 6Pathology Department, Hospital Clinic de Barcelona, Barcelona, Spain; 7Gynaecology and Obstetrics Department, Hospital Clinic de Barcelona, Barcelona, Spain

Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504
Introduction/Background The 2020 WHO classification of gynaecological tumors has introduced as the main criteria for classification of vulvar squamous cell carcinomas (VSCC) their etiological relationship with human papillomavirus (HPV) infection, dividing VSCC into two categories: HPV-associated and HPV-independent VSCC. Additionally, recent evidence suggests that HPV-independent tumors should be further divided according to p53 mutational status. We aimed to evaluate the clinical and prognostic implications of these new criteria.

Methodology We retrospectively identified patients treated for VSCC in our hospital from 1985 to 2022 (n=196). Tumors were reviewed and classified in compliance with 2020 WHO criteria, according to p16 immunohistochemistry and HPV testing. HPV-independent tumors were subclassified as p53 wild-type and mutant. The clinical and pathological features of tumors were compared and disease-free survival (DFS) and disease-specific survival (DSS) were evaluated using univariate and multivariate analysis.

Results Thirty-six (18%) patients had HPV-associated and 160 (82%) HPV-independent tumors, 88% of whom showed mutant p53. Patients with HPV-independent tumors were significantly older (76 vs 62 years, p<0.05) and had bigger tumors (29 vs 20 mm, p<0.05). HPV-independent tumors with mutant p53 were more deeply invasive than those with wild-type p53 (8 vs 5 mm, p<0.05). Mean follow-up was 53 months. HPV-independent tumors were associated with shorter DFS (recurrence rate 48% vs 17%, p<0.05), both in the univariate and multivariate analysis (Figure 1). A tendency to worse DSS was identified in patients with HPV-independent tumors, particularly in patients with p53 mutant tumors (mortality rate 15% for p53 mutant, 10% for p53 wild-type, and 5% for HPV-associated VSCC, p=0.2; Figure 1), despite the differences did not reach statistical significance.

Conclusion The 2020 WHO classification of VSCC has clinical and prognostic implications. Among patients with HPV-independent VSCC, patients with mutant p53 show specific clinical features. Different treatment of VSCC patients, according to HPV-association or not, should be considered in the future.